1. Laboratory
  2. Laboratory medicine
  3. COVID-19 test kit
  4. Jiangsu Bioperfectus Technologies Co., Ltd.
  • Products
  • Catalogs
  • News & Trends
  • Exhibitions

COVID-19 test kit JC10308NW series
SARS-COV-2nasopharyngealclinical

COVID-19 test kit
COVID-19 test kit
COVID-19 test kit
Add to favorites
Compare this product
 

Characteristics

Applications
COVID-19
Micro-organism
SARS-COV-2
Sample type
nasopharyngeal, clinical, laboratory
Analysis mode
for real-time PCR
Sample volume

0.005 ml
(0.00017 US fl oz)

Description

COVID-19 Coronavirus (ORF1ab/N/E) Real Time PCR Kit is an In Vitro Diagnostic (IVD) reagent replying on fluorescent PCR technology and aiming at qualitatively detection and differentiation of human RNA from SARS-CoV-2 from upper and lower respiratory tract samples. Primer and probe are selected from Open Reading Frame gene region (ORF1a/b), envelope protein (E) and nucleocapsid region (N) for SARS-CoV-2. The kit is a multiplex assay, run in a single well/vessel, designed for detection and differentiation of RNA from SARS-CoV-2. In addition, the kit also contains human house-keeping gene (RNase P) for clinical sample detection. The product is intended for use on populations suspected to have SARS-CoV-2 infection, as an aid in the diagnosis of SARS-CoV-2 infection by trained laboratory personnel on RT-PCR. Multiplex real-time PCR detect 3 targets specific for SARS-CoV-2 Internal control ensures the whole process reliability Better performance makes the result more accurate More efficient: from sample extraction to RT-PCR report as fast as 60 min Suitable for more mainstream instrument Parameters Target region: ORF1a/b, N gene and E gene Limit of detection: 200 copies/mL

Other Jiangsu Bioperfectus Technologies Co., Ltd. products

Assay

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.